Who leads, who treats, what dose? European paediatric differentiated thyroid carcinoma practice—an European Cooperative Study Group for Paediatric Rare Tumours survey
Authors' conclusion
Across Europe, centres broadly endorse risk-adapted care but diverge at key decision nodes-extent of surgery, formal risk framework, and RAIT in low-risk disease-reflecting guidance plurality and organizational context. Leveraging existing infrastructures offers pragmatic avenues to reduce unwarranted variation while generating paediatric-specific evidence to refine recommendations.
Study context
- Population
- European centres providing paediatric differentiated thyroid carcinoma (DTC) care; one consolidated response per centre from a clinician overseeing paediatric DTCcentres, 18 countries
- Participants
- 42 centres
- Outcome
- Real-world management of paediatric DTC across Europe
Methodological detailsweb-based survey, descriptive, centre-level analyses
- Web-based survey
- Descriptive, centre-level analyses
Main finding
As reported in the abstract
- University or academic hospitals
- ≈75%
- Paediatric age cut-off ≤18 years
- ≈70%
- Dedicated MDT board
- ≈60%
- Hemithyroidectomy usual initial surgery for unilateral presumed low-risk disease; total thyroidectomy less common
- approximately two-thirds to three-quarters of centres
Observational data: associations, not effects.
Original publication
Who leads, who treats, what dose? European paediatric differentiated thyroid carcinoma practice—an European Cooperative Study Group for Paediatric Rare Tumours survey. Eur J Endocrinol. Published 15 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →